Glutamic acid urea compound and preparation method and application thereof, nuclide targeting probe and preparation method and application thereof, and pharmaceutical composition
By preparing glutamate urea compounds and labeling nuclides to form nuclide-targeting probes, and combining them with the deferasirox structure, the problems of rapid drug metabolism and insufficient tumor uptake in existing PSMA-targeted radioligand therapies have been solved, achieving higher tumor uptake and target site retention, thus improving treatment and diagnostic efficacy.
Patent Information
- Application Number
- CN202411035514.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-08-17
- Filing Date
- 2024-07-31
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-07-31
AI Technical Summary
Existing PSMA-targeted radioligand therapy for prostate cancer has problems such as rapid drug metabolism, insufficient tumor uptake, and high radiation dose to healthy organs. Furthermore, the application and modification of derarosi in the design of radionuclide-targeted drugs has difficulty in improving tumor targeting and lesion enrichment rate.
Develop glutamate urea compounds and their pharmaceutically acceptable salts, form radionuclide-targeting probes through coordination reactions with labeled radionuclides, bind to the deferasirox structure, improve the tumor uptake value and target site retention time of the probes, and optimize pharmacokinetic properties.
It significantly improved the uptake and retention time of radionuclide-targeted probes in tumors, enhanced the diagnosis and treatment of PSMA protein-mediated diseases, provided higher lesion uptake and retention time, and improved the efficacy of existing PSMA-targeted therapies.
Smart Images

Figure CN118955478A_ABST
Abstract
Description
[0001] This application claims the priority of the Chinese patent application filed with the State Intellectual Property Office on August 17, 2023, with application number CN2023110358835 and invention name "Glutamate urea compounds and preparation methods and applications thereof, radionuclide targeted probes and preparation methods and applications thereof, and pharmaceutical compositions", the entire contents of which are incorporated by reference into this application. Technical Field
[0002] The present invention belongs to the field of biomedicine technology, and specifically relates to glutamate urea compounds and preparation methods and applications thereof, pharmaceutically acceptable salts of glutamate urea compounds, radionuclide targeting probes and preparation methods and applications thereof, pharmaceutically acceptable salts of radionuclide targeting probes, and pharmaceutical compositions. Background Art
[0003] Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein that is overexpressed in approximately 90% of prostate cancers. Therefore, PSMA-targeted radioligand therapy (RLT) has become a potentially valuable therapeutic strategy for metastatic castration-resistant prostate cancer (mCRPC). In addition, PSMA expression has also been found in other solid tumors, so PSMA can be used as a therapeutic target for a variety of tumors. In recent years, various PSMA-targeted radioligands have been developed, which have shown good prospects in early clinical evaluations. The leading position in this field is [ 177 Lu]Lu-PSMA617, many studies have shown that [ 177 Lu]Lu-PSMA617 RLT has good safety and efficacy in a large number of mCRPC patients. However, due to the rapid metabolism of the drug in the body, the single dose is often large, and many patients have an insufficient response to radioligand therapy and experience disease progression during or after treatment.
[0004] One of the strategies to enhance the therapeutic effect is to improve the delivery of radioligands. The commonly used method is to increase the tumor uptake dose by conjugating albumin binding groups to PSMA-targeted radioligands to prolong the blood residence time. For example, albumin binding groups such as iodophenylbutyric acid, Evans blue or ibuprofen can be modified into PSMA probes to achieve higher tumor uptake. However, this strategy often also increases the irradiation dose of healthy organs and tissues (including kidneys and bone marrow). Therefore, the pharmacokinetic properties of the probe in vivo must be carefully regulated. In summary, it is of great significance to develop a PSMA-targeted probe with a short blood circulation cycle, high absolute tumor uptake, long lesion retention, and low background in non-target organs.
[0005] Deferasirox (DFX) is an oral iron chelator, which is often used to reduce the iron content in patients with transfusion-dependent anemia and non-transfusion-dependent thalassemia. Studies have shown that deferasirox has certain tumor targeting properties. After it is enriched in the tumor site, it has an anti-tumor cell proliferation effect. It can be used as a chemotherapy drug, and it has also been reported to have roles as an antifungal drug and an antibacterial drug. However, how to modify deferasirox so that it can have better tumor targeting, a higher lesion enrichment rate, and a better disease treatment effect is a difficult problem facing researchers. In addition, the value of the deferasirox structure in the design of radionuclide targeted drugs has not yet been developed. It is still unknown how much influence it has on the pharmacokinetic properties of the probe after hybridization with other receptor targeting groups, and its role in the field of radionuclide targeted diagnosis and treatment needs to be explored. Summary of the invention
[0006] In view of this, the object of the present invention is to provide glutamate urea compounds and preparation methods and applications thereof, pharmaceutically acceptable salts of glutamate urea compounds, radionuclide targeting probes and preparation methods and applications thereof, pharmaceutically acceptable salts of radionuclide targeting probes, and pharmaceutical compositions. The glutamate urea compounds and pharmaceutically acceptable salts thereof, radionuclide targeting probes and pharmaceutically acceptable salts thereof provided by the present invention all have PSMA targeting performance, have long target organ retention time, high tumor uptake dose and low background.
[0007] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions.
[0008] The present invention provides a glutamic acid urea compound having the structure shown in Formula I-1 and Formula I-2:
[0009]
[0010]
[0011] Among them, either R1 or R2 is The other is a group to be labeled, which includes any one of the following structures:
[0012]
[0013] X is present or absent, and when X is present, it includes Linker 1 or Linker 2;
[0014] The linking group 1 includes any one of the following structures:
[0015]
[0016] The linking group 2 includes any one of the following structures:
[0017]
[0018] wherein n, m, y, z, p and q are independently integers between 0 and 10.
[0019] The present invention provides a method for preparing the glutamic acid urea compound described in the above technical scheme.
[0020] (i) When X does not exist or is a linking group 1, the preparation method comprises the following steps:
[0021] The polypeptide compound 1 is subjected to a first substitution reaction with the R1 active compound to obtain an intermediate 1;
[0022] The intermediate 1 is subjected to a R3 protecting group removal reaction and then subjected to a second substitution reaction with an R2 active compound to obtain the glutamic acid urea compound;
[0023] Any one of the R1 active compound and the R2 active compound is When , the other is any of the following structures:
[0024]
[0025] When the polypeptide compound 1 is When the intermediate 1 is
[0026]
[0027] When the polypeptide compound 1 is When the intermediate 1 is
[0028]
[0029] X and R1 in the polypeptide compound 1 and intermediate 1 are the same as X and R1 in the formula I-1 and formula I-2; R3 includes a Boc protecting group, a DDE protecting group or a Fmoc protecting group;
[0030] (ii) When X is a linking group 2, the preparation method comprises the following steps:
[0031] The polypeptide compound 2 is subjected to a third substitution reaction with R1-L to obtain an intermediate 2;
[0032] The intermediate 2 is subjected to a fourth substitution reaction with the R2 active compound to obtain the glutamic acid urea compound;
[0033] In the R1-L, L includes any one of the following structures:
[0034]
[0035] p and q in said L are the same as those in said linking group 2;
[0036] When R1 in R1-L is When the R2 active compound is any one of the following structures:
[0037]
[0038] When R1 in R1-L is the group to be labeled, the R2 active compound is
[0039] When the polypeptide compound 2 is When the intermediate 2 is
[0040] When the polypeptide compound 2 is When the intermediate 2 is
[0041] X and R1 in the polypeptide compound 2 and intermediate 2 are the same as X and R1 in the formula I-1 and formula I-2.
[0042] The present invention provides a pharmaceutically acceptable salt of a glutamate urea compound, which is obtained by reacting a glutamate urea compound with an acid or a base; the glutamate urea compound is the glutamate urea compound described in the above technical scheme or the glutamate urea compound prepared by the preparation method described in the above technical scheme.
[0043] The present invention provides a nuclide targeting probe, which is obtained by a coordination reaction between a group to be labeled in the glutamate urea compound described in the above technical solution or a pharmaceutically acceptable salt of the glutamate urea compound described in the above technical solution and a labeled nuclide.
[0044] Preferably, the labeled nuclide comprises 18 F. 47 Sc, 64 Cu, 67 Cu, 67 Ga, 68 Ga, 89 Zr, 86 Y. 89 Sr. 90 Y. 99m Tc, 105 Rh, 109 Pd, 111 In, 119 Sb, 149 Tb, 153 Sm, 157 Gd,161 Tb, 166 Ho, 177 Lu, 186 Re, 188 Re, 201 Tl, 203 Pb, 212 Pb, 212 Bi, 213 Bi, 223 Ra, 227 Th and 225 At least one of Ac.
[0045] The present invention provides a method for preparing the nuclide targeting probe described in the above technical scheme, comprising the following steps: subjecting a glutamate urea compound or a pharmaceutically acceptable salt thereof to a coordination reaction with a labeled nuclide to obtain a nuclide targeting probe or a pharmaceutically acceptable salt of the nuclide targeting probe; the glutamate urea compound or a pharmaceutically acceptable salt thereof is the glutamate urea compound described in the above technical scheme or the glutamate urea compound obtained by the preparation method described in the above technical scheme or the pharmaceutically acceptable salt of the glutamate urea compound described in the above technical scheme.
[0046] The present invention provides a pharmaceutically acceptable salt of a nuclide targeting probe, which is obtained by a salt-forming reaction of a nuclide targeting probe or a glutamate urea compound; the nuclide targeting probe is the nuclide targeting probe described in the above technical scheme or the nuclide targeting probe prepared by the preparation method described in the above technical scheme; the glutamate urea compound is the glutamate urea compound described in the above technical scheme or the glutamate urea compound prepared by the preparation method described in the above technical scheme.
[0047] The present invention provides a pharmaceutical composition, comprising an active component and a pharmaceutically acceptable excipient; the active component comprises one or more of a glutamate urea compound, a radionuclide targeting probe, a pharmaceutically acceptable salt of a glutamate urea compound, and a pharmaceutically acceptable salt of the radionuclide targeting probe described in the above technical scheme; the glutamate urea compound is the glutamate urea compound described in the above technical scheme or the glutamate urea compound obtained by the preparation method described in the above technical scheme; the radionuclide targeting probe is the radionuclide targeting probe described in the above technical scheme or the radionuclide targeting probe obtained by the preparation method described in the above technical scheme.
[0048] The present invention provides use of the glutamate urea compounds described in the above technical scheme, the glutamate urea compounds prepared by the preparation method described in the above technical scheme, the pharmaceutically acceptable salts of the glutamate urea compounds described in the above technical scheme, the nuclide targeting probe described in the above technical scheme, the nuclide targeting probe prepared by the preparation method described in the above technical scheme, the pharmaceutically acceptable salts of the nuclide targeting probe described in the above technical scheme, or the pharmaceutical composition described in the above technical scheme in the preparation of therapeutic drugs or diagnostic drugs for PSMA protein-mediated diseases.
[0049] Preferably, the PSMA protein-mediated disease includes tumors.
[0050] The glutamate urea compound provided by the present invention is a compound modified with deferasirox. Deferasirox has a certain targeting ability for tumor lesions, and has been approved as an iron chelator for clinical application, and has good safety. The present invention modifies the structure of deferasirox into the PSMA targeting probe, which significantly improves the uptake value of the probe at the target site and prolongs the retention time of the probe at the target site. The glutamate urea compound provided by the present invention can be applied to the labeling of a variety of diagnostic and therapeutic nuclides, and can also be used to construct an imaging treatment platform based on diagnostic and therapeutic nuclides, and has a good application prospect in the preparation of therapeutic drugs or diagnostic drugs for PSMA protein-mediated diseases.
[0051] The glutamate urea compounds provided by the present invention can chelate with the nuclide through the labeled group to form a PSMA-targeted nuclide probe with high affinity and high specificity, which has the characteristics of strong labeling ability, short labeling time, and high labeling yield, and is conducive to the commercial application and clinical promotion of nuclide targeted probes. Compared with the existing PSMA targeted probes, the nuclide targeted probes provided by the present invention have suitable metabolic kinetic properties (different pharmacokinetic properties) and high lesion uptake and retention time, and have excellent diagnostic and therapeutic effects on PSMA protein-mediated diseases. It is a nuclide targeted diagnostic and therapeutic drug with great application prospects. As shown in the test results of the embodiment, the nuclide targeted probes provided by the present invention have suitable metabolic kinetic properties (different pharmacokinetic properties) and high lesion uptake and retention time. 177 The absolute value of uptake of Lu-labeled radionuclide targeting probe in tumors is [ 177Lu]Lu-PSMA617 (one of the current gold standards) is 4 to 5 times that of Lu, and is a radionuclide targeted therapy drug with great application prospects. It overcomes the defects of the existing small molecule PSMA, such as rapid metabolism and short retention time in target organs, improves the effect of PSMA radionuclide targeted therapy, and has the potential for clinical promotion and application. In addition to treatment, the radionuclide targeted probe provided by the present invention is distributed in the body to form a concentration difference. If the emitted rays or magnetic flux changes are detected by external instruments, an image is formed after reconstruction, which can provide diagnostic information for the disease and achieve the effect of integrated diagnosis and treatment. In addition, by adjusting the appropriate specific activity or drug combination, it is helpful to obtain a better target / non-target ratio and enhance the uptake of radionuclide targeted probes in tumors. BRIEF DESCRIPTION OF THE DRAWINGS
[0052] Figure 1 This is the mass spectrometry identification spectrum of compound PKND01;
[0053] Figure 2 This is the mass spectrometry identification spectrum of compound PKND02;
[0054] Figure 3 This is the mass spectrometry identification spectrum of compound PKSD01;
[0055] Figure 4 This is the mass spectrometry identification spectrum of compound PKSD02;
[0056] Figure 5 This is the mass spectrometry identification spectrum of compound PKSP2D01;
[0057] Figure 6 This is the mass spectrometry identification spectrum of compound Gd-PKND01;
[0058] Figure 7 HPLC identification spectra of compounds PKND01 (a), PKND02 (b), PKSD01 (c), PKSD02 (d) and PKSP2D01 (e);
[0059] Figure 8 This is the HPLC identification chart of the probe Gd-PKND01;
[0060] Fig. 9 For the probe 68 Ga]Ga-PKND01(a), [ 68 Ga]Ga-PKND02(b), [ 68 Ga]Ga-PKSD01(c) and [ 68 Radiochemical purity HPLC identification chart of Ga]Ga-PKSP2D01 (d);
[0061] Fig.10 For the probe177 Lu]Lu-PKND01(a),[ 177 Lu]Lu-PKND02(b) and [ 177 Lu]Radiochemical purity HPLC identification chart of Lu-PKSD01 (c);
[0062] Fig.11 For the probe 68 Ga]Ga-PKND01(a), [ 68 Ga]Ga-PKND02(b) and [ 68 The stability HPLC identification results of Ga]Ga-PKSD01(c);
[0063] Fig.12 For the probe 177 Lu]Lu-PKND01(a),[ 177 Lu]Lu-PKND02(b) and [ 177 Lu] Lu-PKSD01 (c) stability HPLC identification results;
[0064] Fig.13 For the probe 177 Lu]Lu-PKND01(a) and [ 177 Lu] Lu-PKND02 (b) cellular uptake and inhibition results;
[0065] Fig.14 For the probe 177 Lu]Lu-PKSD01(a) and [ 177 Lu] Lu-PKSD02 (b) cellular uptake and inhibition results;
[0066] Fig.15 for[ 68 PET imaging results of Ga]Ga-PKND01 (a) and quantitative uptake values of tissues of interest (b);
[0067] Fig.16 for[ 68 PET imaging results of Ga]Ga-PKND02 (a) and quantitative uptake values of tissues of interest (b);
[0068] Fig.17 for[ 68 PET imaging results of Ga]Ga-PKSD01 (a) and quantitative uptake values of tissues of interest (b);
[0069] Fig.18 for[ 68 PET imaging results of Ga]Ga-PKSP2D01 (a) and quantitative uptake values of tissues of interest (b);
[0070] Fig.19 for[ 177 SPECT imaging results (a) and target / non-target ratio (b) of Lu]Lu-PKND01;
[0071] Fig. 20 for[ 177 SPECT imaging results (a) and target / non-target ratio (b) of Lu]Lu-PKND02;
[0072] Fig.21 for[ 177 SPECT imaging results (a) and target / non-target ratio (b) of Lu]Lu-PKSD01;
[0073] Fig. 22 for[ 177 SPECT imaging results of Lu]Lu-PSMA617 (a), [ 177 Lu]Lu-PKND01 and [ 177 Lu] Lu-PKSD01 uptake counts in tumor sites and [ 177 Lu]Lu-PSMA617 ratio (b);
[0074] Fig.23 For different specific activities [ 177 SPECT imaging tumor uptake results (a) and tumor / kidney ratio (b) of Lu]Lu-PKND01;
[0075] Fig.24 The magnetic resonance imaging results of tumor-bearing mice at different time points before and after tail vein injection of Gd-PKND01;
[0076] Fig.25 for[ 177 Biodistribution results of Lu]Lu-PKND01 in tumor-bearing mice (a) and tumor / kidney ratios at different time points (b);
[0077] Fig.26 for[ 177 Lu] Lu-PSMA617 biodistribution results in tumor-bearing mice (a) and [ 177 Lu] Lu-PSMA617 uptake values in tumors and [ 177 Lu]Lu-PKND01 comparison results (b);
[0078] Fig. 27 for[ 177 Lu]Lu-PKND01, [ 177 Lu]Lu-PKSD01 and [ 177 Lu]Lu-PSMA617 treatment results in tumor-bearing mice;
[0079] Fig.28 This is the mass spectrum identification diagram of compound PK2ND01;
[0080] Fig.29 This is the mass spectrum identification diagram of compound PK2NGD01;
[0081] Fig.30 This is the mass spectrum identification diagram of compound PKED01;
[0082] Fig.31 This is the mass spectrum identification diagram of compound PKE3D01;
[0083] Fig.32 Compound PKP 22 Mass spectrometry identification of D01;
[0084] Fig.33 For the probe 68 Ga]Ga-PK2ND01 and [ 68 Radiochemical purity HPLC identification chart of Ga]Ga-PK2NGD01;
[0085] Fig.34 For the probe 68 Ga]Ga-PKED01,[ 68 Ga]Ga-PKE3D01 and [ 68 Ga]Ga-PKP 22 Radiochemical purity HPLC identification chart of D01;
[0086] Fig.35 For the probe 177 Lu] Lu-PKE3D01 cellular uptake and inhibition results (a), cellular internalization and membrane uptake rate (b);
[0087] Fig.36 for[ 68 PET imaging results of Ga]Ga-PK2ND01 (a) and quantitative uptake values of tissues of interest (b);
[0088] Fig.37 for[ 68 PET imaging results of Ga]Ga-PK2NGD01 (a) and quantitative uptake values of tissues of interest (b);
[0089] Fig.38 for[ 68 PET imaging results of Ga]Ga-PKED01 (a) and quantitative uptake values of tissues of interest (b);
[0090] Fig.39 for[ 68PET imaging results of Ga]Ga-PKE3D01 (a) and quantitative uptake values of tissues of interest (b);
[0091] Fig.40 for[ 68 Ga]Ga-PKP 22 PET imaging results of D01 (a) and quantitative uptake values of tissues of interest (b). DETAILED DESCRIPTION
[0092] The present invention provides a glutamic acid urea compound having the structure shown in Formula I-1 and Formula I-2:
[0093]
[0094] Among them, either R1 or R2 is The other is a group to be labeled, which includes any one of the following structures:
[0095]
[0096] X is present or absent, and when X is present, it includes Linker 1 or Linker 2;
[0097] The linking group 1 includes any one of the following structures:
[0098]
[0099] The linking group 2 includes any one of the following structures:
[0100]
[0101] wherein n, m, y, z, p and q are independently integers between 0 and 10.
[0102] In the present invention, when X is absent, either R1 or R2 is Another one is The glutamate urea compound includes PKND01, PKND02, PK2ND01 or PK2NGD01:
[0103]
[0104]
[0105] In the present invention, when X is When either R1 or R2 is Another one is The glutamate urea compounds include PKSD01, PKSD02, PKSP2D01 or PKSP2D02:
[0106]
[0107]
[0108] In the present invention, when X is When any one of R1 and R2 is Another one is The glutamate urea compounds include PKP 23 D01, PKP 23 D02, PKP 22 D01, PKP 22 D02, PKED01, PKED02, PKDD01, PKDD02, PKD2D01, PKD3D01, PKE2D01, or PKE3D01:
[0109]
[0110]
[0111]
[0112]
[0113] The present invention provides a method for preparing the glutamic acid urea compound described in the above technical solution. When X does not exist or is a connecting group 1, the preparation method comprises the following steps:
[0114] The polypeptide compound 1 is subjected to a first substitution reaction with the R1 active compound to obtain an intermediate 1;
[0115] The intermediate 1 is subjected to a R3 protecting group removal reaction and then subjected to a second substitution reaction with an R2 active compound to obtain the glutamic acid urea compound;
[0116] Any one of the R1 active compound and the R2 active compound is When , the other is any of the following structures:
[0117]
[0118] When the polypeptide compound 1 is When the intermediate 1 is
[0119] When the polypeptide compound 1 is When the intermediate 1 is
[0120] X and R1 in the polypeptide compound 1 and intermediate 1 are the same as X and R1 in the formula I-1 and formula I-2; R3 includes a Boc protecting group, a DDE protecting group or a Fmoc protecting group.
[0121] Unless otherwise specified, the materials and equipment used in the present invention are all commercially available products in the art.
[0122] In the present invention, the polypeptide compound 1 is subjected to a first substitution reaction with the R1 active compound to obtain an intermediate 1.
[0123] In the present invention, the molar ratio of the polypeptide compound 1 to the R1 active compound is preferably 1:1-5, more preferably 1:2-3. In the present invention, the first substitution reaction is preferably carried out in the presence of a high boiling point solvent and an alkaline reagent; the high boiling point solvent preferably includes one or more of N-methylpyrrolidone (NMP), dimethyl sulfoxide (DMSO) and N,N-dimethylformamide (DMF); the present invention has no special limitation on the amount of the high boiling point solvent, as long as the polypeptide compound 1 can be dissolved and the first substitution reaction can be carried out smoothly. In the present invention, the alkaline reagent is preferably an organic base, and the organic base preferably includes triethylamine (TEA) and / or N,N-diisopropylethylamine (DIPEA); the molar ratio of the polypeptide compound 1 to the alkaline reagent is preferably 1:1-10, more preferably 1:3-5. In the present invention, the temperature of the first substitution reaction is preferably 25-60°C, more preferably 25-40°C, and the time of the first substitution reaction is preferably 1-24h, more preferably 5-12h.
[0124] After the first substitution reaction, the present invention preferably further comprises a post-treatment, and the post-treatment preferably comprises: subjecting the obtained first substitution system to a reverse phase high performance chromatography column purification and then freeze drying to obtain intermediate 1. In the present invention, the conditions for the reverse phase high performance chromatography column purification include: the chromatographic column is a reverse phase C18 semi-preparative column; the mobile phase A is preferably water + 0.1% trifluoroacetic acid (TFA), and the mobile phase B is preferably acetonitrile + 0.1% TFA; the elution method is preferably gradient elution, and the conditions for the gradient elution are preferably 0 to 30 min: the volume fraction of the mobile phase B increases from 10% to 90%, and the flow rate of the mobile phase is preferably 3 mL / min. The present invention has no special restrictions on the temperature and time of the freeze drying, and freeze drying to constant weight (i.e., freeze drying) is sufficient.
[0125] After obtaining the intermediate 1, the present invention performs a second substitution reaction on the intermediate 1 after removing the R3 protecting group and then performs a second substitution reaction with the R2 active compound to obtain the glutamic acid urea compound.
[0126] In the present invention, the R3 protection group removal reaction is preferably carried out in the presence of a hydrazine hydrate solution or trifluoroacetic acid; the mass fraction of hydrazine hydrate in the hydrazine hydrate solution is preferably 1 to 10%, more preferably 3 to 5%; the present invention has no special restrictions on the amount of the hydrazine hydrate solution and trifluoroacetic acid, as long as the protecting group (DDE, Boc or Fmoc) can be removed. In the present invention, the temperature of the R3 protection group removal reaction is preferably 0 to 37°C, more preferably 25°C, and the time of the R3 protection group removal reaction is preferably 1 to 12h, more preferably 2 to 5h.
[0127] In the present invention, the conditions of the second substitution reaction and the post-treatment after the second substitution reaction are preferably the same as the conditions and post-treatment of the first substitution reaction, and will not be described in detail here.
[0128] In the present invention, when X does not exist or is a linker group 1, the preparation route of the glutamic acid urea compound is as follows:
[0129] Preparation route of formula I-1;
[0130] Preparation route of formula 1-2.
[0131] The present invention provides a method for preparing the glutamic acid urea compound described in the above technical solution. When X is a connecting group 2, the preparation method comprises the following steps:
[0132] The polypeptide compound 2 is subjected to a third substitution reaction with R1-L to obtain an intermediate 2;
[0133] The intermediate 2 is subjected to a fourth substitution reaction with the R2 active compound to obtain the glutamic acid urea compound;
[0134] In the R1-L, L includes any one of the following structures:
[0135]
[0136] p and q in said L are the same as those in said linking group 2;
[0137] When R1 in R1-L is When the R2 active compound is any one of the following structures:
[0138]
[0139] When R1 in R1-L is the group to be labeled, the R2 active compound is
[0140] When the polypeptide compound 2 is When the intermediate 2 is
[0141] When the polypeptide compound 2 is When the intermediate 2 is
[0142] X and R1 in the polypeptide compound 2 and intermediate 2 are the same as X and R1 in the formula I-1 and formula I-2.
[0143] In the present invention, when X is a linking group 2, the preparation route of the glutamic acid urea compound is as follows:
[0144] Preparation route of formula I-1;
[0145] Preparation route of formula 1-2.
[0146] In the present invention, the polypeptide compound 2 is subjected to a third substitution reaction with R1-L to obtain an intermediate 2.
[0147] In the present invention, the R1-L preferably includes DFX-MAL, DOTA-MAL or DFX-P2-MAL:
[0148]
[0149] In the present invention, the molar ratio of the polypeptide compound 2 to the third active compound is preferably 1:1-5, more preferably 1:1.5-2. In the present invention, the third substitution reaction is preferably carried out in the presence of a solvent, and the solvent preferably includes a high boiling point solvent and / or PBS (phosphate buffer solution), more preferably a mixed solvent of a high boiling point solvent and PBS; the high boiling point solvent preferably includes one or more of N-methylpyrrolidone (NMP), dimethyl sulfoxide (DMSO) and N,N-dimethylformamide (DMF); the pH value of the PBS is preferably 7-8, more preferably 7.4-7.6; the present invention has no special restrictions on the amount of the solvent, as long as the polypeptide compound 2 can be dissolved and the third substitution reaction can be smoothly carried out. In the present invention, the temperature and time of the third substitution reaction and the post-treatment after the third substitution reaction are preferably the same as the temperature, time and post-treatment of the first substitution reaction, and will not be repeated here.
[0150] After obtaining the intermediate 2, the present invention conducts a fourth substitution reaction between the intermediate 2 and the R2 active compound to obtain the glutamic acid urea compound.
[0151] In the present invention, the R2 active compound preferably includes a DOTA or DFX active compound with an active reactive group -NHS or -SCN. In the present invention, the molar ratio of the intermediate 2 to the R2 active compound is preferably 1:1 to 5, more preferably 1:2 to 2.5. In the present invention, the conditions of the fourth substitution reaction and the post-treatment after the fourth substitution reaction are preferably the same as the conditions and post-treatment of the first substitution reaction, and will not be repeated here.
[0152] The present invention provides a pharmaceutically acceptable salt of a glutamic acid urea compound, which is obtained by reacting a glutamic acid urea compound with an acid or a base; the glutamic acid urea compound is the glutamic acid urea compound described in the above technical scheme or the glutamic acid urea compound prepared by the preparation method described in the above technical scheme. In the present invention, the pharmaceutically acceptable salt preferably includes trifluoroacetate, phosphate, formates, acetates, potassium salts or sodium salts. In the present invention, the acid preferably includes trifluoroacetic acid, hydrochloric acid, formic acid or acetic acid; the base preferably includes potassium hydroxide or sodium hydroxide. The present invention does not specifically limit the conditions of the reaction, and the conditions of the salt-forming reaction well known to those skilled in the art can be used.
[0153] The present invention provides a radionuclide targeting probe, which is obtained by a coordination reaction between a to-be-labeled group in the glutamic acid urea compound or a pharmaceutically acceptable salt thereof and a labeled radionuclide. In the present invention, the labeled radionuclide includes 18 F. 47 Sc, 64 Cu, 67 Cu, 67 Ga, 68 Ga, 89 Zr, 86 Y. 89 Sr. 90 Y. 99m Tc, 105 Rh, 109 Pd, 111 In, 119 Sb, 149 Tb, 153 Sm, 157 Gd, 161 Tb, 166 Ho, 177 Lu, 186 Re, 188 Re, 201 Tl, 203 Pb, 212 Pb, 212 Bi, 213 Bi, 223 Ra, 227 Th and225 At least one of Ac, more preferably 177 Lu, 68 Ga, 64 Cu, 18 F. 90 Y or 225 Ac.
[0154] The present invention provides a method for preparing the nuclide targeting probe described in the above technical solution, comprising the following steps:
[0155] The glutamate urea compound is subjected to a coordination reaction with a labeled nuclide to obtain a nuclide targeting probe; the glutamate urea compound is the glutamate urea compound described in the above technical solution or the glutamate urea compound prepared by the preparation method described in the above technical solution. In the present invention, the nuclide targeting probe is preferably prepared by a wet labeling method or a freeze-drying labeling method.
[0156] In the present invention, the wet labeling method for preparing the nuclide targeting probe preferably includes the following steps: mixing a solution of glutamate urea compound with a labeled nuclide solution, performing coordination reaction and then diluting to obtain an injection solution of the nuclide targeting probe.
[0157] In the present invention, the solvent in the solution of glutamate urea compounds preferably includes one or more of a buffer solution, water and an organic solvent; the buffer solution preferably includes an acetic acid-acetate solution or an aluminum chloride-acetate solution, and the pH value of the buffer solution is preferably 3-7, more preferably 4-6.5; the concentration of aluminum chloride in the aluminum chloride-acetate solution is preferably 0.2-1 g / L, more preferably 0.4 g / L; the acetate in the acetic acid-acetate solution and the aluminum chloride-acetate solution independently includes one or more of sodium acetate, potassium acetate and ammonium acetate; the concentration of the solution of glutamate urea compounds is preferably 0.001-1000 mg / mL, more preferably 0.01-1 mg / mL. In the present invention, the ratio of the mass of the glutamate urea compound to the radioactivity of the labeled nuclide in the labeled nuclide solution is preferably 20-400 μg: 1 kBq-1000 GBq, more preferably 20-400 μg: 0.037-74000 MBq, and further preferably 20-200 μg: 0.037-7400 MBq. In the present invention, there is no special limitation on the labeled nuclide solution, and a labeled nuclide solution well known to those skilled in the art can be used, such as gadolinium chloride hexahydrate (GdCl3·6H2O) solution, 68 GaCl3 hydrochloric acid solution or 177 LuCl3 solution; 68 The GaCl3 hydrochloric acid solution is preferably obtained by elution from a germanium gallium generator.
[0158] In the present invention, the temperature of the coordination reaction is preferably 25 to 100°C, more preferably 80 to 100°C, and the time of the coordination reaction is preferably 10 to 60 min, more preferably 20 to 30 min. When the temperature of the coordination reaction is higher than room temperature, the present invention preferably further comprises cooling the obtained coordination reaction system to room temperature after the coordination reaction. The present invention has no special limitation on the cooling, and a cooling method familiar to those skilled in the art may be adopted, such as natural cooling. After the dilution, the present invention preferably further comprises aseptically filtering the obtained dilution system to obtain an injection of a nuclide targeted probe. In the present invention, the dilution preferably utilizes physiological saline or water for injection. In the present invention, the radioactivity concentration of the injection of the nuclide targeted probe is preferably 0.037 to 3700 MBq / mL.
[0159] In the present invention, when the labeled nuclide solution is a gadolinium chloride hexahydrate solution, the present invention preferably first uses a base to adjust the pH value of the mixed solution of the glutamic acid urea compound and the gadolinium chloride hexahydrate solution to 5.0-6.5, more preferably 5.5-6.0, the base preferably includes a KOH solution, and the concentration of the KOH solution is preferably 1-4 mol / L, more preferably 2-3 mol / L.
[0160] In the present invention, the preparation of the nuclide targeting probe by freeze-drying labeling method preferably includes the following steps: freeze-drying the solution of glutamic acid urea compound and sealing it to obtain a freeze-dried medicine box; adding a solvent to the freeze-dried medicine box to dissolve it, and then adding the labeled nuclide solution to carry out coordination reaction and dilution to obtain the injection of the nuclide targeting probe. In the present invention, the freeze drying is preferably to pack the solution of glutamic acid urea compound into a freeze-drying container and then freeze-dry it; the present invention has no special restrictions on the freeze-drying conditions, and the freeze-drying conditions familiar to those skilled in the art can be used. The present invention preferably adds auxiliary materials to the freeze-dried medicine box as needed, and the auxiliary materials preferably include at least one of excipients, antioxidants and acid-base regulators. The present invention has no special restrictions on the excipients, antioxidants and acid-base regulators, and the excipients, antioxidants and acid-base regulators familiar to those skilled in the art can be used. In the present invention, the other preparation conditions of the nuclide targeting probe are preferably the same as those of the aforementioned wet labeling method, and will not be repeated here.
[0161] In the present invention, when the radiochemical purity of the injection of the nuclide targeted probe prepared by the wet labeling method and the freeze-drying labeling method is lower than 95%, it is preferred to further include purifying the injection of the nuclide targeted probe, and the purification is preferably Sep-Pak C18 separation column purification, and the Sep-PakC18 separation column is preferably activated and eluted with anhydrous ethanol and water in sequence before use. In the present invention, the eluents used for the purification are preferably water and anhydrous ethanol in sequence, and the eluent of anhydrous ethanol is collected and the solvent is removed, and then diluted to obtain an injection of a high-purity nuclide targeted probe. In the present invention, the dilution is preferably performed using physiological saline or water for injection. In the present invention, the radioactivity concentration of the injection of the high-purity nuclide targeted probe is preferably 0.037 to 3700 MBq / mL.
[0162] The preparation method provided by the present invention has the advantages of simple and easy labeling, good stability of the obtained radionuclide targeting probe, high tumor uptake, etc., and is suitable for industrial production and clinical promotion.
[0163] In the present invention, a pharmaceutically acceptable salt of a nuclide targeting probe is provided, which is obtained by a salt-forming reaction of a nuclide targeting probe or a glutamate urea compound; the nuclide targeting probe is the nuclide targeting probe described in the above technical solution or the nuclide targeting probe prepared by the preparation method described in the above technical solution; the glutamate urea compound is the glutamate urea compound described in the above technical solution or the glutamate urea compound prepared by the preparation method described in the above technical solution. In the present invention, the pharmaceutically acceptable salt preferably includes trifluoroacetate, phosphate, formate, acetate, potassium salt or sodium salt. The present invention does not specifically limit the preparation method of the pharmaceutically acceptable salt of the nuclide targeting probe, and the preparation method of the pharmaceutically acceptable salt well known to those skilled in the art can be adopted.
[0164] The present invention provides a pharmaceutical composition, comprising an active component and a pharmaceutically acceptable excipient; the active component comprises one or more of a glutamate urea compound, a nuclide targeting probe, a pharmaceutically acceptable salt of the glutamate urea compound described in the above technical solution, and a pharmaceutically acceptable salt of the nuclide targeting probe described in the above technical solution; the glutamate urea compound is the glutamate urea compound described in the above technical solution or the glutamate urea compound prepared by the preparation method described in the above technical solution; the nuclide targeting probe is the nuclide targeting probe described in the above technical solution or the nuclide targeting probe prepared by the preparation method described in the above technical solution. The present invention has no special restrictions on the pharmaceutically acceptable excipients, and pharmaceutically acceptable excipients well known to those skilled in the art can be used. In the present invention, when the active component comprises a nuclide targeting probe and / or a pharmaceutically acceptable salt of a nuclide targeting probe, the dosage form of the pharmaceutical composition is preferably an injection, preferably administered by intravenous injection; when the active component does not contain a nuclide targeting probe and a pharmaceutically acceptable salt thereof, the present invention has no special restrictions on the dosage form and administration method of the pharmaceutical composition, and dosage forms and administration methods well known to those skilled in the art can be used.
[0165] The present invention also provides the use of the glutamate urea compound described in the above technical solution, the glutamate urea compound prepared by the preparation method described in the above technical solution, the pharmaceutically acceptable salt of the glutamate urea compound described in the above technical solution, the nuclide targeting probe described in the above technical solution, the nuclide targeting probe prepared by the preparation method described in the above technical solution, the pharmaceutically acceptable salt of the nuclide targeting probe described in the above technical solution, or the pharmaceutical composition described in the above technical solution in the preparation of therapeutic drugs or diagnostic drugs for PSMA protein-mediated diseases. In the present invention, the PSMA protein-mediated disease preferably includes tumors; the tumor preferably includes one or more of prostate cancer, breast cancer, ovarian cancer, liver cancer, lung cancer, colorectal cancer, bone tissue sarcoma, connective tissue sarcoma, renal cell carcinoma, gastric cancer, pancreatic cancer, nasopharyngeal carcinoma, head and neck cancer, neuroendocrine tumors and skin melanoma. In the present invention, the diagnostic method preferably includes single photon emission computed tomography (SPECT), positron emission tomography (PET) and magnetic resonance imaging (MRI); the treatment method preferably includes radionuclide targeted therapy and / or chemotherapy.
[0166] In order to further illustrate the present invention, the glutamate urea compounds and their preparation methods and applications, the radionuclide targeting probes and their preparation methods and applications, and the pharmaceutical compositions of the present invention are described in detail below in conjunction with the accompanying drawings and examples, but they should not be construed as limiting the scope of protection of the present invention.
[0167] Example 1
[0168] Synthesis of PKND01
[0169]
[0170] (1) Synthesis of compound 2: Weigh compound 1 (3.16 μmol) into a 1.5 mL centrifuge tube, add DMSO (0.5 mL) to dissolve, add raw material DFX-NHS (9.49 μmol) and N,N-diisopropylethylamine (DIPEA, 15.82 μmol), react at 25°C for 12 h, HPLC purification and freeze-drying (freeze-drying temperature -65°C) to obtain white solid compound 2 (4 mg, yield 97%, purity 98%). HPLC purification conditions: reverse phase C18 semi-preparative column (10 mm × 250 mm); mobile phase A: water + 0.1% trifluoroacetic acid (TFA); mobile phase B: acetonitrile + 0.1% TFA; gradient elution conditions: 0-30 min: the volume fraction of mobile phase B increases from 10% to 90%, and the mobile phase flow rate is 3 mL / min. Compound 2: ESIMS [M+H] + for C 70 H 83 N 10 O 15 ,calcd 1303.60,found1303.25.
[0171] (2) Synthesis of PKND01: Compound 2 (3.06 μmol) was weighed into a 1.5 mL centrifuge tube, hydrazine hydrate (0.5 mL, mass fraction 3%) was added thereto, and the mixture was reacted at 25°C for 2 h, then DMSO (0.5 mL), DOTA-NHS (5.48 μmol) and DIPEA (10.98 μmol) were added, and the mixture was stirred at 25°C for 12 h, purified by HPLC and freeze-dried (freeze-drying temperature -65°C) to obtain compound PKND01 (1.6 mg, yield 47.7%), and the purity was determined to be greater than 95%. HPLC purification conditions: reverse phase C18 semi-preparative column (10 mm × 250 mm); mobile phase A: water + 0.1% trifluoroacetic acid (TFA); mobile phase B: acetonitrile + 0.1% TFA; gradient elution conditions: 0-30 min: the volume fraction of mobile phase B increased from 10% to 90%, and the mobile phase flow rate was 3 mL / min. PKND01: ESIMS[M+H] + for C 76 H 97 N 14 O 20 ,calcd 1525.69,found1525.88,such as Figure 1 As shown; HPLC purity analysis as Figure 7 As shown in a, the purity is greater than 95%.
[0172]
[0173] According to the preparation method of PKND01, the DDE-protected lysine fragment in compound 1 was replaced with a 2,7-diaminoheptanoic acid fragment (compound 1-K2) to obtain the PK2ND01 product.
[0174] According to the preparation method of PKND01, the DDE-protected lysine fragment in compound 1 was replaced with a 2,7-diaminoheptanoic acid fragment (compound 1-K2), and DOTA-NHS was replaced with DOTA-GA to obtain the PK2NGD01 product.
[0175] According to the preparation method of PKND01, the DDE-protected lysine fragment in compound 1 was replaced with compound 1-KE to obtain the PKED01 product.
[0176] According to the preparation method of PKND01, the DDE-protected lysine fragment in compound 1 was replaced with compound 1-KE3 to obtain the PKE3D01 product.
[0177] According to the preparation method of PKND01, the DDE-protected lysine fragment in compound 1 was replaced with compound 1-KP22 to obtain PKP 22 D01 product.
[0178] Compounds PK2ND01, PK2NGD01, PKED01, PKE3D01, PKP 22 The mass spectrometry identification diagrams of D01 are as follows Fig.28 , Fig.29 , Fig.30 , Fig.31 , Fig.32 shown.
[0179] Example 2
[0180] Synthesis of PKND02 compounds
[0181]
[0182] (1) Synthesis of compound 3: Weigh compound 1 (3.16 μmol) into a 1.5 mL centrifuge tube, add DMSO (0.5 mL) to dissolve, add raw materials DOTA-NHS (7.91 μmol) and N,N-diisopropylethylamine (DIPEA, 15.82 μmol), react at 25°C for 12 h, HPLC purification and freeze-drying (freeze-drying temperature -65°C) to obtain white solid compound 3 (3.7 mg, yield 88%, purity 98%). HPLC purification conditions: reverse phase C18 semi-preparative column (10 mm × 250 mm); mobile phase A: water + 0.1% trifluoroacetic acid (TFA); mobile phase B: acetonitrile + 0.1% TFA; gradient elution conditions: 0-30 min: the volume fraction of mobile phase B increases from 10% to 90%, and the mobile phase flow rate is 3 mL / min. Compound 3: ESIMS [M+H] + for C 65 H 96 N 11 O 19 ,calcd 1335.53,found 1335.24.
[0183] (2) Synthesis of PKND02: Compound 3 (3.06 μmol) was weighed and placed in a 1.5 mL centrifuge tube. Hydrazine hydrate (0.5 mL, mass fraction 3%) was added thereto. After reacting at 25°C for 2 h, DMSO (0.5 mL) was added, and DOTA-NHS (5.34 μmol) and DIPEA (6.41 μmol) were added. The mixture was stirred at 25°C for 12 h. HPLC purification and freeze-drying (freeze-drying temperature -65°C) were performed to obtain compound PKND02 (2 mg, yield 61.53%), which was identified to have a purity greater than 95%. HPLC purification conditions: reverse phase C18 semi-preparative column (10 mm × 250 mm); mobile phase B: acetonitrile + 0.1% TFA; gradient elution conditions: 0-30 min: the volume fraction of mobile phase B increased from 10% to 90%, and the mobile phase flow rate was 3 mL / min. PKND02: ESIMS [M+H] + forC 76 H 97 N 14 O 20 ,calcd 1525.69,found 1525.39,as Figure 2 As shown; HPLC purity analysis as Figure 7 The purity shown in b is greater than 95%.
[0184] Example 3
[0185] Synthesis of PKSD01 compounds
[0186]
[0187] (1) Synthesis of compound 5: Weigh compound 4 (3.03 μmol) in a 1.5 mL centrifuge tube, add DMSO (0.5 mL) to dissolve, add raw material DFX-MAL (6.05 μmol), and then add PBS solution (0.3 mL). At 25°C, react for 12 h, HPLC purification and freeze-drying (freeze-drying temperature -65°C) to obtain white solid compound 5 (2 mg, yield 48.78%, purity 98%). HPLC purification conditions: reverse phase C18 semi-preparative column (10 mm × 250 mm); mobile phase B: acetonitrile + 0.1% TFA; gradient elution conditions: 0-30 min: the volume fraction of mobile phase B increases from 10% to 90%, and the mobile phase flow rate is 3 mL / min. ESIMS [M+H] + forC 68 H 81 N 12 O 16 S,calcd 1354.52,found 1354.34.
[0188] (2) Synthesis of compound PKSD01: Compound 5 (2 mg, 1 eq., 1.48 μmol) was weighed and placed in a 1.5 mL centrifuge tube. DMSO (0.5 mL) was added, followed by DOTA-NHS (1.85 mg, 2.5 eq., 3.69 μmol) and DIPEA (0.7 mg, 4 eq., 5.91 μmol). The mixture was stirred at 25 °C for 12 h, purified by HPLC and freeze-dried (freeze-drying temperature -65 °C) to obtain compound PKSD01 (1 mg, yield 38.91%), which was identified to have a purity greater than 95%. HPLC purification conditions: reverse phase C18 semi-preparative column (10 mm × 250 mm); mobile phase A: water + 0.1% trifluoroacetic acid (TFA); mobile phase B: acetonitrile + 0.1% TFA; gradient elution conditions: 0-30 min: the volume fraction of mobile phase B increased from 10% to 90%, and the mobile phase flow rate was 3 mL / min. PKSD01: ESIMS[M+H] + for C 76 H 97 N 14 O 20 ,calcd 1739.73,found 1739.70,as Figure 3 As shown; HPLC purity analysis as Figure 7 The purity shown in c is greater than 95%.
[0189] Example 4
[0190] Synthesis of PKSD02 compounds
[0191]
[0192] (1) Synthesis of compound 6: Weigh compound 4 (2.33 μmol) in a 1.5 mL centrifuge tube, add DMSO (0.5 mL) to dissolve, add raw material DOTA-MAL (4.66 μmol), and then add PBS solution (0.3 mL). React at 25°C for 12 h, HPLC purification and freeze-drying (freeze-drying temperature -65°C) to obtain white solid compound 6 (2.1 mg, yield 65.01%, purity 98%). HPLC purification conditions: reverse phase C18 semi-preparative column (10 mm × 250 mm); mobile phase B: acetonitrile + 0.1% TFA; gradient elution conditions: 0-30 min: the volume fraction of mobile phase B increases from 10% to 90%, and the mobile phase flow rate is 3 mL / min. Compound 6: ESIMS [M+H] + for C 63 H 94 N 13 O 20 S,calcd 1385.57,found 1385.48.
[0193] (2) Synthesis of compound PKSD02: Weigh compound 6 (1.52 μmol) in a 1.5 mL centrifuge tube, add DMSO (0.5 mL), DFX-NHS (3.79 μmol) and DIPEA (4.55 μmol), stir at 25°C for 12 h, HPLC purification and freeze-drying (freeze-drying temperature -65°C) to obtain compound PKSD02 (1 mg, yield 37.87%), and the purity was determined to be greater than 95%. HPLC purification conditions: reverse phase C18 semi-preparative column (10 mm × 250 mm); mobile phase A: water + 0.1% trifluoroacetic acid (TFA); mobile phase B: acetonitrile + 0.1% TFA; gradient elution conditions: 0-30 min: the volume fraction of mobile phase B increased from 10% to 90%, and the mobile phase flow rate was 3 mL / min. PKSD02: ESIMS [M+H] + for C 84 H 107 N 16 O 23 S,calcd 1740.92,found1740.63,as Figure 4 As shown; HPLC purity analysis as Figure 7 The purity shown in (d) is greater than 95%.
[0194] Example 5
[0195] Synthesis of PKSP2D01 compounds
[0196]
[0197] (1) Synthesis of compound 7: Weigh compound 4 (3.5 μmol) and DFX-P2-MAL (5.24 μmol) in a 1.5 mL centrifuge tube, add DMSO (0.3 mL) and PBS (pH = 7.4) to dissolve, react at 25 ° C for 12 h, HPLC purification and freeze-drying (freeze-drying temperature -65 ° C) to obtain white solid compound 7 (1.3 mg, yield 24.6%, purity 95%). HPLC purification conditions: reverse phase C18 semi-preparative column (10 mm × 250 mm); mobile phase A: water + 0.1% trifluoroacetic acid (TFA); mobile phase B: acetonitrile + 0.1% TFA; gradient elution conditions: 0-30 min: the volume fraction of mobile phase B increases from 10% to 90%, and the mobile phase flow rate is 3 mL / min. Compound 7: ESIMS [M+H] + for C 75 H 94 N 13 O 19 S,calcd 1513.70,found1513.53.
[0198] (2) Synthesis of PKSP2D01: Compound 7 (0.86 μmol) was weighed into a 1.5 mL centrifuge tube, and DOTA-NHS (1.72 μmol) and DIPEA (4.3 μmol) were added thereto. The mixture was stirred at 25°C for 12 h, purified by HPLC and freeze-dried (freeze-drying temperature -65°C) to obtain compound PKSP2D01 (1.0 mg, yield 59.9%), and the purity was determined to be greater than 95%. HPLC purification conditions: reverse phase C18 semi-preparative column (10 mm × 250 mm); mobile phase A: water + 0.1% trifluoroacetic acid (TFA); mobile phase B: acetonitrile + 0.1% TFA; gradient elution conditions: 0-30 min: the volume fraction of mobile phase B increased from 10% to 90%, and the mobile phase flow rate was 3 mL / min. PKSP2D01: ESIMS [M+H] + for C 91 H 120 N 17 O 26 S,calcd1900.11,found 1899.83,as Figure 5 As shown; HPLC purity analysis as Figure 7 The purity shown in e is greater than 95%.
[0199] Example 6
[0200] Gd nuclide labeling
[0201] The compound PKND01 and gadolinium chloride hexahydrate (GdCl3·6H2O) were dissolved in a mixed solvent (DMSO:H2O volume ratio = 1:1) at a molar ratio of 1:2, and then the pH was adjusted to 6.0 with KOH solution, heated to 60°C and shaken for 12 hours. After the reaction was completed, it was purified by HPLC to obtain the radionuclide targeted probe Gd-PKND01, wherein the usage ratio of the compound PKND01 to the mixed solvent was 1 mg:1 mL.
[0202] HPLC analysis conditions: reverse phase C18 analytical column (4.6 mm × 250 mm); mobile phase A: water + 0.1% trifluoroacetic acid (TFA); mobile phase B: acetonitrile + 0.1% TFA; gradient elution conditions: 0-30 min: the volume fraction of mobile phase B increases from 10% to 90%, and the mobile phase flow rate is 1 mL / min. The mass spectrometry identification and HPLC identification of chemical purity of Gd-PKND01 are shown in the table below. Figure 6 and Figure 8 . ESIMS[M+H] + for C 76 H 93 G JZ 14 O 20 ,calcd 1679.91,found 1680.55.
[0203] Example 7
[0204] 68 Ga nuclide labeling
[0205] Wet method: 370MBq 68 GaCl3 hydrochloric acid solution (eluted from the germanium-gallium generator) was added to 0.5 mL of acetic acid-acetate solution containing glutamic acid urea compound (20 μg) prepared in Examples 1 to 5, respectively, and reacted at 90°C for 20 min, then cooled to room temperature, diluted with physiological saline or water for injection, and sterile filtered to obtain a radionuclide targeting probe injection (the concentration of the radionuclide targeting probe is 110 MBq / mL).
[0206] Lyophilization method: a certain amount of buffer (sodium acetate buffer, pH 5.5, 0.4 mL) and 370 MBq 68 GaCl3 eluent (eluted from a gallium germanium generator) was added to a freeze-dried drug box containing 20 μg of glutamic acid urea compounds, reacted at 90°C for 20 minutes, cooled to room temperature, diluted with physiological saline or water for injection, and sterile filtered to obtain a radionuclide targeted probe injection (the concentration of the radionuclide targeted probe was 110 MBq / mL).
[0207] If the radiochemical purity is less than 95%, it can be purified by C18 separation column to remove unreacted 68 Ga3 + C18 separation column purification steps: Take a Sep-Pak C18 separation column and activate it by eluting it with 10 mL of anhydrous ethanol and 10 mL of water. Dilute the marker solution with 10 mL of water and load it onto the separation column. Rinse the separation column with water to remove unreacted 68 Ga ions, and then washed with ethanol solution to obtain 68 Ga-labeled radionuclide targeting probe.
[0208] [ 68 Ga]Ga-PKND01, [ 68 Ga]Ga-PKND02, [ 68 Ga]Ga-PKSD01 and [ 68 The radiochemical purity HPLC identification results of Ga]Ga-PKSP2D01 are shown in Fig. 9 In a, b, c and d, the radiochemical purity of each radionuclide targeting probe is greater than 95%.
[0209] [ 68 Ga]Ga-PK2ND01, [ 68 The radiochemical purity HPLC identification results of Ga]Ga-PK2NGD01 are shown in Fig.33 ;[ 68 Ga]Ga-PKED01,[ 68 Ga]Ga-PKE3D01 and [ 68 Ga]Ga-PKP 22 The radiochemical purity HPLC identification results of D01 are shown in Fig.34 .
[0210] Example 8
[0211] 177 Lu nuclide labeling
[0212] Wet method: 370MBq 177 LuCl3 solution was added to 0.2 mL of acetic acid-acetate solution containing the compound prepared in Examples 1 to 3 (20 μg), respectively, reacted at 90°C for 20 min, cooled to room temperature, diluted with physiological saline or water for injection, and sterile filtered to obtain a radionuclide targeting probe injection (the concentration of the radionuclide targeting probe was 110 MBq / mL).
[0213] Lyophilization method: 0.2 mL of buffer (sodium acetate buffer, pH = 5.5) and 370 MBq of 177LuCl3 solution was added to the freeze-dried drug box containing glutamic acid urea compound (20 μg), mixed and dissolved, and then placed at 90°C for reaction for 20 minutes, cooled to room temperature, diluted with physiological saline or water for injection, and sterile filtered to obtain the radionuclide targeting probe injection (the concentration of the radionuclide targeting probe was 110 MBq / mL).
[0214] If the radiochemical purity is less than 95%, it can be purified by C18 separation column to remove unreacted 177 Lu 3 + The purification steps of C18 separation column are as follows: Take Sep-Pak C18 separation column, activate and elute it with 10mL of anhydrous ethanol and 10mL of water. Dilute the labeled solution with 10mL of water and load it onto the separation column. Rinse the separation column with water to remove unreacted 177 Lu ions, and then washed with ethanol solution to obtain 177 Lu-labeled radionuclide targeting probe.
[0215] [ 177 Lu]Lu-PKND01, [ 177 Lu]Lu-PKND02, [ 177 Lu]Lu-PKSD01 and [ 177 The radiochemical purity HPLC identification results of Lu]Lu-PKE3D01 are shown in Fig.10 In a, b, c and d, the radiochemical purity of each probe was greater than 95%.
[0216] Test Example 1
[0217] Evaluation of stability and lipid-water distribution properties
[0218] 1. Injection stability experiment: The radionuclide targeted probe diluted with physiological saline was placed at room temperature for different time periods, and samples were taken for analysis by HPLC. HPLC analysis conditions: reverse phase C18 analytical column (4.6 mm × 250 mm); mobile phase A: water + 0.1% trifluoroacetic acid (TFA); mobile phase B: acetonitrile + 0.1% TFA; gradient elution conditions: 0-30 min: the volume fraction of mobile phase B increased from 10% to 90%, and the mobile phase flow rate was 1 mL / min.
[0219] [ 68 Ga]Ga-PKND01, [ 68 Ga]Ga-PKND02 and [ 68 The stability HPLC identification results of Ga]Ga-PKSD01 are shown in Fig.11 a, b and c; [ 177 Lu]Lu-PKND01, [ 177 Lu]Lu-PKND02 and [177 The stability HPLC identification results of Lu]Lu-PKSD01 are shown in Fig.12 a, b and c. Figures 11-12 It can be seen that at the tested time point, the radiochemical purity of each radionuclide targeting probe was greater than 95%, indicating that it was stable in the specified solution.
[0220] 2. Determination of lipid-water distribution coefficient (logP):
[0221] 100 μL of the diluted solution containing the radionuclide targeting probe was added to a centrifuge tube containing a mixture of 2.9 mL PBS and 3 mL n-octanol. After vortexing for 3 minutes, the solution was centrifuged at 10,000 rpm for 3 minutes. 100 μL of liquid was taken from each of the aqueous phase and n-octanol phase and the radioactivity count was determined by a γ-counter. The experiment was repeated three times and the average value was taken. The calculation formula for logP is:
[0222] P=I 有机相 / I 水相 ;
[0223] Among them I 有机相 represents the radioactive count measured in the organic phase, I 水相 Represents the radioactive count measured in the aqueous phase. The lipid-water distribution coefficient of each radiolabeled targeting probe was finally determined by calculation. The results are shown in Table 1. The measured radionuclide targeting probes are water-soluble.
[0224] Table 1 Lipid-water distribution coefficient of radionuclide targeting probe
[0225] Probe LogP <![CDATA[[ 177 Lu]Lu-PKND01]]> -2.31±0.16 <![CDATA[[ 177 Lu]Lu-PKND02]]> -2.07±0.06 <![CDATA[[ 177 Lu]Lu-PKSD01]]> -2.21±0.04 <![CDATA[[ 177 Lu]Lu-PKSD02]]> -2.09±0.03 <![CDATA[[ 177 Lu]Lu-PKE3D01]]> -2.20±0.08
[0226] As can be seen from Table 1, the above five 117 The Lu-labeled nuclide targeting probe is water-soluble, indicating that the 117 Lu-labeled radionuclide targeting probes can be metabolized by the kidneys, avoiding nonspecific uptake of radioactivity by normal tissues.
[0227] Test Example 2
[0228] Cellular uptake and inhibition assays
[0229] PC3 PIP cells with high PSMA expression and PC3 flu cells with negative PSMA expression were plated in a 24-well plate containing culture medium (containing fetal bovine serum and double antibody) (cell counting plate counted the number of cells, about 200,000 / well) and cultured for 24 hours. At the beginning of the uptake experiment, the original culture medium was aspirated, washed twice with PBS (500μL), and the PBS was aspirated; an equal amount of the probe to be tested diluted with culture medium was added to each well, and incubated at 37°C for 0.5, 1, 2, 4 and 8 hours; after the incubation at each time point was completed, the culture medium was aspirated, and sodium hydroxide (NaOH) solution (500μL, 1M) was added to each well to lyse the cells. After 5 minutes, the lysed cells were placed in a disposable centrifuge tube to measure the radioactivity count; the count was divided by the total amount of added radioactivity to obtain the cell uptake percentage.
[0230] In order to investigate the targeting specificity of the probe PSMA, an inhibition group was also set up in this study, that is, an appropriate amount of inhibitor PSMA617 was added to each well of cells before adding the radionuclide-labeled probe, and the cells were incubated at 37°C for 2h and 4h; after the incubation, the radioactive culture medium was aspirated, and sodium hydroxide solution (500μL, 1M) was added to each well to lyse the cells. After 5 minutes, the lysed cells were placed in a disposable centrifuge tube to measure the radioactivity count; the count was divided by the total amount of added radioactivity to obtain the cell uptake percentage.
[0231] [ 177 Lu]Lu-PKND01, [ 177 Lu]Lu-PKND02, [ 177 Lu]Lu-PKSD01 and [ 177 The cellular uptake and inhibition results of Lu]Lu-PKSD02 are shown in Figures 13-14 As shown. Taking the results of 4h as an example, each radionuclide targeting probe was significantly taken up in PSMA-positive cells, while the uptake in negative cells was significantly reduced. The uptake of each radionuclide targeting probe in PSMA-positive cells can be inhibited by PSMA617, indicating that the radionuclide targeting probe provided by the present invention has specific targeting to PSMA protein. [ 177 The cellular uptake and inhibition results of Lu]Lu-PKE3D01 are shown in Fig.35 As shown. The uptake of radionuclide targeted probe in PSMA positive expression cells at each time point was significantly higher than that in PSMA negative expression cells and inhibition group. In addition, [ 177 The internalization rate of Lu]Lu-PKE3D01 in PSMA-positive cells was significantly higher than the membrane binding rate, proving that the probe can enter the cells and exert its effect.
[0232] Test Example 3
[0233] PET imaging test
[0234] The radiochemical purity of the prepared samples is greater than 95%. 68 After the Ga-labeled radionuclide targeted probe was diluted with physiological saline, 0.2 mL (1 MBq) of injection solution was injected through the tail vein of PC3 PIP model mice. MicroPET imaging was performed at different time points, and the region of interest (ROI) was outlined on the image. The probe distribution value was obtained by calculation. 68 Ga]Ga-PKND01, [ 68 Ga]Ga-PKND02, [ 68 Ga]Ga-PKSD01, [ 68 Ga]Ga-PKSP2D01, [ 68 Ga]Ga-PK2ND01, [ 68 Ga]Ga-PK2NGD01, [ 68 Ga]Ga-PKED01,[ 68 Ga]Ga-PKE3D01 and [ 68 Ga]Ga-PKP 22 The PET imaging results of D01 are as follows: Fig.15 , Fig.16 , Fig.17 , Fig.18 , Fig.36 , Fig.37 , Fig.38 , Fig.39 and Fig.40 As shown in the figure, the radionuclide targeted probe has a higher uptake in the tumor site. The bladder and kidneys have higher radioactive signals, which means that the radionuclide targeted probe is excreted through urine. Over time, the absolute uptake of the tumor and the target / non-target ratio increased significantly.
[0235] Test Example 4
[0236] SPECT imaging experiment
[0237] Tumor-bearing mice were injected with 14 MBq via tail vein 177 Lu-labeled radionuclide targeted probes were subjected to static SPECT scanning imaging at different time points after injection, and CT scanning was used to assist in positioning. After imaging, the images were reconstructed and the regions of interest (ROI) in the mouse images were delineated to obtain the radioactivity count values, and the target / non-target ratio of the probe distribution was calculated. 177 Lu]Lu-PKND01, [ 177 Lu]Lu-PKND02 and [ 177 The SPECT imaging results of Lu]Lu-PKSD01 are as follows Fig.19 , Fig. 20 and Fig.21 As shown. Control group [ 177The SPECT imaging results of Lu]Lu-PSMA617 are as follows Fig. 22 As shown. During the monitoring time range, [ 177 Lu]Lu-PKND01, [ 177 Lu]Lu-PKND02 and [ 177 The enrichment of Lu-PKSD01 nuclide targeted probe in tumor sites was significantly higher than that in the control group. 177 Lu]Lu-PSMA617, and the imaging contrast is high and the lesion outline is clear, which proves that the radionuclide targeted probe provided by the present invention has a good tumor uptake effect. Over time, the radioactive background in the blood pool and other normal organs is gradually cleared, and the target / non-target ratio is continuously improved. The above data show that the radionuclide targeted probe provided by the present invention is relatively 177 Lu]Lu-PSMA617 has better radionuclide targeted therapy potential.
[0238] Fig.23 For different specific activities [ 177 SPECT imaging of tumor uptake results (a) and tumor / kidney ratio (b) of Lu]Lu-PKND01. SPECT imaging experiments were used to compare different specific activities [ 177 Distribution of Lu]Lu-PKND01 (by adding different amounts of PKND01 into the labeling solution) in tumor-bearing mice. Fig.23 It can be seen that when the specific activity is 14MBq / nmol, [ 177 Lu]Lu-PKND01 has both good tumor uptake and a high tumor / kidney ratio.
[0239] Test Example 5
[0240] MRI imaging experiment
[0241] Gd-PKND01 compound was dissolved in PBS buffer and injected into tumor-bearing mice via tail vein at a dose of 11.9 μmol / kg. MRI imaging was performed at 1, 3, 6, 12, 24, and 48 h after injection. Fig.24 As shown, the area indicated by the arrow is the tumor location. Compared with before injection, the PC3-pip tumor shows a gradually enhanced signal after injection, indicating that the radionuclide targeting probe provided by the present invention has a good enrichment effect at the tumor site.
[0242] Test Example 6
[0243] Biodistribution experiments
[0244] Tumor-bearing mice were injected with 1.5 MBq [ 177 Lu]Lu-PKND01 or [ 177Lu]Lu-PSMA617. Mice were killed at different time points after injection, and tumor and other organ tissue samples were obtained by dissection, weighed, and radioactivity counts were measured using a gamma counter. The results were expressed as the percentage of uptake dose per gram of tissue or organ (%ID / g). 177 Lu]Lu-PKND01 and [ 177 The biodistribution results of Lu]Lu-PSMA617 were as follows Fig.25 and Fig.26 As shown. 4h after injection, [ 177 Lu] Lu-PKND01 tumor uptake was greater than 80% ID / g. 24h after injection, the tumor uptake value reached 150% ID / g, and remained at 60% ID / g at 96h. 177 Lu]Lu-PSMA617, the nuclide targeting probe provided by the present invention [ 177 Lu]Lu-PKND01 has significantly enhanced tumor uptake and prolonged retention time.
[0245] Test Example 7
[0246] Radionuclide targeted therapy trial
[0247] The tumor-bearing mice were divided into experimental group, 177 There were 6 to 8 mice in each group. Each mouse in the experimental group was injected with different doses of [ 177 Lu]Lu-PKND01 or [ 177 Lu]Lu-PKSD01; [ 177 Each mouse in the Lu-PSMA617 control group was injected with 37MBq[ 177 Each mouse in the saline group was injected with the same volume of saline via the tail vein, and the tumor size and body weight were monitored every day. Fig. 27 As shown, compared with the saline group, the tumor volume in the experimental group decreased significantly over time. 177 Lu]Lu-PKND01 have obvious tumor treatment effects. And low doses of [ 177 Lu]Lu-PKND01 or [ 177 Lu]Lu-PKSD01 (9.5MBq) and high dose [ 177 The therapeutic effect is comparable to that of Lu]Lu-PSMA617 (37MBq), indicating that the radionuclide targeting probe provided by the present invention shows good application potential.
[0248] Although the above-mentioned embodiments have made a detailed description of the present invention, they are only some embodiments of the present invention, rather than all embodiments. People can also obtain other embodiments based on the embodiments of the present invention without creative work, and these embodiments all fall within the scope of protection of the present invention.
Claims
1. A glutamic acid urea compound, characterized in that: It has the structure shown in Formula I-1 or Formula I-2: Among them, either R1 or R2 is The other is a group to be labeled, which includes any one of the following structures: X is present or absent, and when X is present, it includes Linker 1 or Linker 2; The linking group 1 includes any one of the following structures: The linking group 2 includes any one of the following structures: wherein n, m, y, z, p and q are independently integers between 0 and 10.
2. The method for preparing the glutamic acid urea compound according to claim 1, characterized in that: (i) When X does not exist or is a linking group 1, the preparation method comprises the following steps: The polypeptide compound 1 is subjected to a first substitution reaction with the R1 active compound to obtain an intermediate 1; The intermediate 1 is subjected to a R3 protecting group removal reaction and then subjected to a second substitution reaction with an R2 active compound to obtain the glutamic acid urea compound; Any one of the R1 active compound and the R2 active compound is When , the other is any of the following structures: When the polypeptide compound 1 is When the intermediate 1 is When the polypeptide compound 1 is When the intermediate 1 is X and R1 in the polypeptide compound 1 and intermediate 1 are the same as X and R1 in the formula I-1 and formula I-2; R3 includes a Boc protecting group, a DDE protecting group or a Fmoc protecting group; (ii) When X is a linking group 2, the preparation method comprises the following steps: The polypeptide compound 2 is subjected to a third substitution reaction with R1-L to obtain an intermediate 2; The intermediate 2 is subjected to a fourth substitution reaction with the R2 active compound to obtain the glutamic acid urea compound; In the R1-L, L includes any one of the following structures: p and q in said L are the same as those in said linking group 2; When R1 in R1-L is When the R2 active compound is any one of the following structures: When R1 in R1-L is the group to be labeled, the R2 active compound is When the polypeptide compound 2 is When the intermediate 2 is When the polypeptide compound 2 is When the intermediate 2 is X and R1 in the polypeptide compound 2 and intermediate 2 are the same as X and R1 in the formula I-1 and formula I-2.
3. A pharmaceutically acceptable salt of a glutamic acid urea compound, characterized in that: The glutamate urea compound is obtained by reacting a glutamate urea compound with an acid or a base; the glutamate urea compound is the glutamate urea compound described in claim 1 or the glutamate urea compound obtained by the preparation method described in claim 2.
4. A radionuclide targeting probe, characterized in that: The glutamate urea compound according to claim 1 or the pharmaceutically acceptable salt of the glutamate urea compound according to claim 3 is obtained by a coordination reaction between the group to be labeled and the labeled nuclide.
5. The nuclide targeting probe according to claim 4, characterized in that:The labeled nuclides include 18 F. 47 Sc, 64 Cu, 67 Cu, 67 Ga, 68 Ga, 89 Zr, 86 Y. 89 Sr. 90 Y. 99m Tc, 105 Rh, 109 Pd, 111 In, 119 Sb, 149 Tb, 153 Sm, 157 Gd, 161 Tb, 166 Ho, 177 Lu, 186 Re, 188 Re, 201 Tl, 203 Pb, 212 Pb, 212 Bi, 213 Bi, 223 Ra, 227 Th and 225 At least one of Ac.
6. The method for preparing the nuclide targeting probe according to claim 4 or 5, characterized in that: The following steps are involved: A glutamate urea compound or a pharmaceutically acceptable salt thereof is subjected to a coordination reaction with a labeled nuclide to obtain a nuclide targeting probe or a pharmaceutically acceptable salt of the nuclide targeting probe; the glutamate urea compound or a pharmaceutically acceptable salt thereof is the glutamate urea compound described in claim 1 or the glutamate urea compound prepared by the preparation method described in claim 2 or the pharmaceutically acceptable salt of the glutamate urea compound described in claim 3.
7. A pharmaceutically acceptable salt of a nuclide targeting probe, characterized in that: It is obtained by salt-forming reaction of a nuclide targeting probe or a glutamate urea compound; the nuclide targeting probe is the nuclide targeting probe described in any one of claims 4 to 5 or the nuclide targeting probe obtained by the preparation method described in claim 6; the glutamate urea compound is the glutamate urea compound described in claim 1 or the glutamate urea compound obtained by the preparation method described in claim 2.
8. A pharmaceutical composition, characterized in that It comprises active components and pharmaceutically acceptable excipients; the active components comprise one or more of glutamate urea compounds, radionuclide targeting probes, pharmaceutically acceptable salts of the glutamate urea compounds according to claim 3, and pharmaceutically acceptable salts of the radionuclide targeting probes according to claim 7; the glutamate urea compounds are the glutamate urea compounds according to claim 1 or the glutamate urea compounds obtained by the preparation method according to claim 2; the radionuclide targeting probes are the radionuclide targeting probes according to any one of claims 4 to 5 or the radionuclide targeting probes obtained by the preparation method according to claim 6.
9. Use of the glutamate urea compound according to claim 1, the glutamate urea compound obtained by the preparation method according to claim 2, the pharmaceutically acceptable salt of the glutamate urea compound according to claim 3, the nuclide targeting probe according to any one of claims 4 to 5, the nuclide targeting probe obtained by the preparation method according to claim 6, the pharmaceutically acceptable salt of the nuclide targeting probe according to claim 7, or the pharmaceutical composition according to claim 8 in the preparation of therapeutic drugs or diagnostic drugs for diseases mediated by PSMA protein.
10. The use according to claim 9, characterized in that: The PSMA protein-mediated diseases include tumors.
Citation Information
Patent Citations
Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
CN108541302A
PSMA targeted radioactive metal complex containing nitro aromatic heterocyclic group and preparation of PSMA targeted radioactive metal complex
CN116507630A
Cell activatable iron chelators
WO2021195064A1
Cited By
Deerasirox derivative, nuclide marker and preparation method and application of deferasirox derivative and nuclide marker
CN119775345A
Glutamate urea compound, preparation method therefor and use thereof, nuclide targeting probe, preparation method therefor and use thereof, and pharmaceutical composition
WO2026040780A1
PSMA-targeting small molecule compound, preparation method therefor, and use thereof, nuclide-labeled probe, preparation method therefor, and use thereof, pharmaceutical composition and use thereof, and kit and use thereof
WO2026137528A1
